

9<sup>th</sup> EFSPi Regulatory Statistics Workshop  
11-13 September 2024  
Basel Switzerland

**Draft program as of 5 June 2024**

11<sup>th</sup> September 2024, 0830-1700 (+2h wine tasting), Day 1

Time	Duration (mins)	Presentation
8:30-8:45	15	<b>Opening remarks</b> Egbert Biesheuvel (EFSPi President, Senior Director Viatris)
8:45-10:45	120	<b>Session 1: Fast to market vs. robustness of the data</b>  Talk 1: How much it matters to be first in class. And how can you catch up? Speaker: Jenny Devenport (Roche)  Panel discussion with the audience
10.45-11.15	30	Coffee break
11:15-13:15	120	<b>Short topics (20 mins per topic): Present problem on 2-3 slides and receive input from a panel of regulators</b>  <i>Chairs: Elina Asikanius (fimea, EMA) and Kaspar Rufibach (Roche)</i>  Topic 1:  Topic 2:  Topic 3:  Topic 4:  Topic 5:  Topic 6:  Please send proposals by 15 August to <a href="mailto:hlyn@novonordisk.com">hlyn@novonordisk.com</a>
13:15-14:45	90	Lunch break and poster session: ESIGs and EFSPi Working Groups
14:45-17:00	135	<b>Session 2: Estimands – Celebrating the 5th anniversary of ICH E9(R1) – what have we learned and where do we need to go?</b>  Talk 1: What has improved and what new issues did we uncover and what issues are we still ignoring? Speakers: Frank Bretz, Novartis and Rob Hemmings, Consilium  Panel discussion with audience
17:00-19:00	120	<b>Wine tasting</b> organised by Hans Ulrich Burger (Roche) and Emmanuel Zuber (Novartis)

12<sup>th</sup> September 2024, 0830-1700, Day 2

Time	Duration (mins)	Presentation

9<sup>th</sup> EFSPi Regulatory Statistics Workshop  
11-13 September 2024  
Basel Switzerland

8.30-10.00	90	<b>Session 3: How can statisticians navigate the interface between the EU Joint Clinical Assessment and EMA regulatory assessment?</b>  Panel discussion with the audience
10.00-10.30	30	Coffee break
10.30-12.30	120	<b>Session 4: Patient centricity</b>  <i>Chairs:</i>  Talk 1: ICH E22 General Considerations for Patient Preference Studies. Speaker: Dr Francesco Pignatti, Rapporteur (EC)  Talk 2: Industry case study. How a patient preference trial impacted the approval/SmPC. Speaker: Brett Hauber, Pfizer  Talk 3: Selecting the treatment – my patient and statistician perspectives. Speaker: Anna Wiksten  Panel discussion with the audience
12.30-14.00	90	Lunch break
14.00-15.30	90	<b>Session 5: Openstatsware - How can we build a scalable ecosystem?</b>  Panel discussion with the audience
15.30-17.00	90	<b>Session 6: Regulatory updates</b>  EMA Speaker: Kit Roes Radboud University, Netherlands  Q&A

13<sup>th</sup> September 2024, 0830-1200, Day 3

Time	Duration (mins)	Presentation
8.30-9.45	75	<b>Session 7: Regulatory landscape in China</b>  Q&A
9.45-10.15	30	Coffee break
10.15-11.45	90	<b>Session 8: The role of innovative statistical methods in pan-European HTA</b>  Panel discussion with the audience
11.45-12.00	15	<b>Closure</b>  Helle Lynggaard (Novo Nordisk, Local Organizing and Scientific Committee)

9<sup>th</sup> EFSPI Regulatory Statistics Workshop  
11-13 September 2024  
Basel Switzerland

**Confirmed posters:**

<b>ESIG/EFSPI Working Group</b>	<b>Title</b>	<b>Author(s)/Presenter(s)</b>
Estimand Implementation Working Group (EIWG)		
EIWG – reporting sub-team		
EIWG – estimands in non-inferiority trials		Sue McKendrick (PPD), David Wright (AstraZeneca), Helle Lynggaard (Novo Nordisk), Chrissie Fletcher (GSK) and Sunita Rehal (GSK)
Launch & Lifecycle		Jenny Devenport (Roche) and Yulia Dyachkova (Merck)
Regulatory ESIG		Alessandro Previtali (BMS), Mark Whitlock (GSK) and Yolanda Barbachano (Biontech)
Statistics Methods Leaders		